Pages that link to "Q43540251"
Jump to navigation
Jump to search
The following pages link to Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms (Q43540251):
Displaying 48 items.
- Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors (Q24676378) (← links)
- The role of pericytes in blood-vessel formation and maintenance (Q24683881) (← links)
- Cell cycle kinases as therapeutic targets for cancer (Q28250447) (← links)
- Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content (Q30479724) (← links)
- Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation (Q33258552) (← links)
- Molecular mechanisms of resistance to tumour anti-angiogenic strategies (Q33718025) (← links)
- Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis (Q33752236) (← links)
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (Q33770680) (← links)
- Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling (Q34309316) (← links)
- Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models (Q34497997) (← links)
- Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer (Q34991189) (← links)
- Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts (Q35102889) (← links)
- The merits of vascular targeting for gynecologic malignancies (Q35116734) (← links)
- Systematic discovery of multicomponent therapeutics (Q35147474) (← links)
- Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches (Q35165648) (← links)
- The impact of anti-angiogenic agents on cancer therapy (Q35299351) (← links)
- Angiogenesis and melanoma - from basic science to clinical trials (Q35380959) (← links)
- Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial. (Q35475535) (← links)
- Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. (Q35569825) (← links)
- Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102 (Q35575875) (← links)
- Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668 (Q35747992) (← links)
- Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy (Q35748830) (← links)
- Pericyte Rho GTPase mediates both pericyte contractile phenotype and capillary endothelial growth state (Q35915992) (← links)
- Clinical implications of angiogenesis in cancers (Q36012979) (← links)
- Hepatic tumor growth: target for angiogenesis inhibition? (Q36038489) (← links)
- Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents (Q36096646) (← links)
- Cyclooxygenase-2 expression and angiogenesis in colorectal cancer (Q36179801) (← links)
- Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes (Q36284948) (← links)
- Antiangiogenic therapy in human gastrointestinal malignancies (Q36591067) (← links)
- Anti‑angiogenic therapy for normalization of tumor vasculature: A potential effect of Buyang Huanwu decoction on nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential (Q36623880) (← links)
- Pericytes on the tumor vasculature: jekyll or hyde? (Q36695062) (← links)
- Pericytes: gatekeepers in tumour cell metastasis? (Q36949861) (← links)
- Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes (Q36962682) (← links)
- Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). (Q37116847) (← links)
- PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival (Q37407269) (← links)
- The pericyte: cellular regulator of microvascular blood flow (Q37424313) (← links)
- Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study (Q37587441) (← links)
- Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance? (Q37846342) (← links)
- Targeting the tumor stroma in hepatocellular carcinoma (Q38366586) (← links)
- Pericytes of the neurovascular unit: key functions and signaling pathways. (Q38844788) (← links)
- Harnessing benefit from targeting tumor associated carbohydrate antigens (Q39032812) (← links)
- Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors (Q39961300) (← links)
- Nilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response (Q41667212) (← links)
- TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model (Q43226884) (← links)
- Paucity of pericytes in germinal matrix vasculature of premature infants. (Q46918337) (← links)
- A phase I surrogate endpoint study of SU6668 in patients with solid tumors. (Q53615730) (← links)
- Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase. (Q54458131) (← links)
- Microenvironment Cell Contribution to Lymphoma Immunity. (Q64997020) (← links)